SARS-CoV-2 vertical transmission without positive nucleic acid testing. The study was also limited by a small sample size. However, these findings show a rapid rate of decline in antibody titers, suggesting lack of protective passive immunity in infants, and IgM detection in infants, supporting a growing body of evidence of possible vertical transmission. We still do not have a correlate of immunity (e.g., we do not know exactly what level of antibody titers are considered protective against infection), and whether infants testing positive by PCR at birth have higher levels of IgM or IgG remains to be seen. More work is needed to understand SARS-CoV-2 immunity in infants; such findings might have implications for potential vaccination efforts.

Acknowledgments
The authors are grateful for the insightful editorial advice provided by Shujie Liao and Dongrui Deng.

This work was funded by Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (grant no. XXGZBDYJ005).

About the Author
Dr. Gao is a physician in the Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Her primary research interests include neonatology and infectious diseases.

References
1. Kimberlin DW, Stagno S. Can SARS-CoV-2 infection be acquired in utero? More definitive evidence is needed. JAMA. 2020 Mar 26 [Epub ahead of print]. https://doi.org/10.1001/jama.2020.4868
2. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–8. https://doi.org/10.1038/s41591-020-0897-1
3. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: the first report. J Infect. 2020;81:147–78. https://doi.org/10.1016/j.jinf.2020.03.012
4. Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, et al. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol. 2020 Apr 24 [Epub ahead of print]. https://doi.org/10.1002/jmv.25932
5. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. Front Med. 2020;14:193–8. https://doi.org/10.1007/s11684-020-0772-y
6. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during pregnancy and possible vertical transmission. Am J Perinatol. 2020 Apr 18 [Epub ahead of print].

7. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. JAMA. 2020;323:1848. https://doi.org/10.1001/jama.2020.4861
8. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA. 2020;323:1846–8. https://doi.org/10.1001/jama.2020.4621

Address for correspondence: Ling Chen, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430030, China; email: chenling@tjh.tjmu.edu.cn; Suhua Chen, Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430030, China; email: tj_csh@163.com

Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents

Arnaud G. L’Huillier,1 Giulia Torriani,1 Fiona Pigny, Laurent Kaiser, Isabella Eckerle

Author affiliation: Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland

DOI: https://doi.org/10.3201/eid2610.202403

Children do not seem to drive transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We isolated culture-competent virus in vitro from 12 (52%) of 23 SARS-CoV-2–infected children; the youngest was 7 days old. Our findings show that symptomatic neonates, children, and teenagers shed infectious SARS-CoV-2, suggesting that transmission from them is plausible.

Children are underrepresented in coronavirus disease (COVID-19) case numbers (1,2). Severity in most children is limited, and children do not seem to be major drivers of transmission (3,4). However, severe acute respiratory syndrome

1These authors contributed equally to this article.
coronavirus 2 (SARS-CoV-2) infects children of all ages (1,3). Despite the high proportion of mild or asymptomatic infections (5), they should be considered as transmitters unless proven otherwise. To address this point, the laboratory of the Geneva University Hospitals and Faculty of Medicine, University of Geneva (Geneva, Switzerland), used cell culture to systematically assess cultivable SARS-CoV-2 in the upper respiratory tract (URT) of 23 children with COVID-19.

All nasopharyngeal specimens (NPS) were collected with a flocked swab in universal transport medium (Floqsawb; Copan, https://www.copan-group.com) and tested for SARS-CoV-2 by reverse transcription PCR during January 25–March 31, 2020 (Appendix, https://wwwnc.cdc.gov/EID/article/26/10/20-2403-App1.pdf). We seeded Vero E6 cells at 8 × 10^4 cells/well in a 24-well plate and inoculated them with 200 μL of viral transport medium the following day. Cells were inoculated for 1 h at 37°C; inoculum was removed; cells were washed once with phosphate buffered saline; and regular cell growth medium containing 10% fetal calf serum was added. We observed cells on days 2, 4, and 6 for cytopathic effect (CPE) by light microscopy. We harvested supernatant at first observation of CPE or, if no CPE occurred, on day 6. For a second passage, we transferred 20 μL of supernatant of CPE-positive specimens onto new Vero E6 cells. We collected supernatant after inoculation and on observation of CPE and confirmed isolation of replication competent SARS-CoV-2 by an increase in viral RNA (Appendix).

Of 638 patients <16 years of age, 23 (3.6%) tested positive for SARS-CoV-2. Median age was 12.0 years (interquartile range [IQR] 3.8–14.5 years, range 7 days–15.9 years). Thirteen patients had an URT infection; 2 each had fever without source and pneumonia (Table). Samples were collected a median of 2 (IQR 1–3) days after symptom onset. Median viral RNA load at diagnosis was 3.0 × 10^6 copies/mL (mean 4.4 × 10^6 [IQR 6.9 × 10^5–4.4 × 10^7] copies/mL; peak 5.3 × 10^6 copies/mL).

We isolated SARS-CoV-2 from 12 (52%) children. We determined SARS-CoV-2 isolation by presence of CPE and increased viral RNA in the supernatant (Table; Appendix Figure). SARS-CoV-2 replication in all 12 positive isolates was confirmed by a second passage.

We isolated virus from children of all ages; the youngest was 7 days of age. Median viral load was higher for patients with isolation (1.7 × 10^6 [mean 7.9 × 10^6, IQR 4.7 × 10^5–1.0 × 10^7] copies/mL) than for those without isolation (6.9 × 10^5 [mean 5.4 × 10^5, IQR 4.2 × 10^5–1.8 × 10^6] copies/mL; p = 0.002) (Figure). Sex, age, duration of symptoms, clinical diagnosis, symptoms, and likelihood of admission did not differ between patients with and without isolation (Appendix Table).

Table. Characteristics and results of children <16 years of age with coronavirus disease, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland, January 25–March 31, 2020*

| Patient | Age | Days from symptom onset to diagnosis | Clinical diagnosis | Hospital admission | Viral RNA copies/mL | Isolate |
|---------|-----|-------------------------------------|-------------------|-------------------|--------------------|---------|
| 1       | 12.6 y | 1                                   | URTI              | No                | 2.8 × 10^6         | Negative |
| 2       | 5.7 y  | 1                                   | URTI              | No                | 1.8 × 10^6         | Negative |
| 3       | 14.8 y | 1                                   | URTI              | No                | 9.9 × 10^6         | Positive |
| 4       | 12.0 y | 2                                   | Obstructive bronchitis | No             | 6.9 × 10^3         | Negative |
| 5       | 3.9 y  | 4                                   | URTI              | No                | 4.5 × 10^3         | Negative |
| 6       | 13.9 y | 2                                   | Pneumonia         | Yes               | 8.6 × 10^3         | Positive |
| 7       | 9.0 y  | 2                                   | Croup             | No                | 6.2 × 10^3         | Negative |
| 8       | 10.1 y | 3                                   | URTI              | No                | 3.3 × 10^3         | Negative |
| 9       | 3 mo   | Not reported                        | Not reported      | Yes               | 2.8 × 10^3         | Negative |
| 10      | 2.2 y  | Not reported                        | Not reported      | Yes               | 5.9 × 10^3         | Negative |
| 11      | 6.4 y  | 1                                   | URTI              | No                | 5.6 × 10^3         | Negative |
| 12      | 7 d    | 1                                   | URTI              | No                | 1.3 × 10^3         | Positive |
| 13      | 12.9 y | 4                                   | Pneumonia         | Yes               | 4.2 × 10^3         | Negative |
| 14      | 15.7 y | Not reported                        | Not reported      | No                | 2.5 × 10^3         | Negative |
| 15      | 12.3 y | 2                                   | Influenza-like illness | No             | 1.1 × 10^3         | Positive |
| 16      | 15.9 y | 1                                   | Fever without source | Yes           | 2.2 × 10^3         | Positive |
| 17      | 1 mo   | 0                                   | Fever without source | Yes           | 5.3 × 10^3         | Positive |
| 18      | 2 mo   | 1                                   | URTI              | No                | 4.4 × 10^3         | Positive |
| 19      | 5.9 y  | 1                                   | URTI              | No                | 1.6 × 10^3         | Positive |
| 20      | 15.9 y | 2                                   | URTI              | No                | 6.8 × 10^3         | Positive |
| 21      | 14.4 y | 5                                   | URTI              | Yes               | 1.4 × 10^3         | Positive |
| 22      | 14.6 y | 3                                   | URTI              | No                | 1.2 × 10^4         | Positive |
| 23      | 14.4 y | 2                                   | URTI              | No                | 3.0 × 10^6         | Positive |

*URTI, upper respiratory tract infection.
Our data show that viral load at diagnosis is comparable to that of adults (6,7) and that symptomatic children of all ages shed infectious virus in early acute illness, a prerequisite for further transmission. Isolation of infectious virus was largely comparable with that of adults, although 2 specimens yielded an isolate at lower viral load (1.2 × 10⁴ and 1.4 × 10⁵ copies/mL) (6).

A limitation of our study was the small number of children assessed. However, although the Canton of Geneva was a region severely affected by SARS-CoV-2 (8), only 23 cases were diagnosed in children at our hospital during the study period. These findings confirm that children are not a major risk group for COVID-19. Another limitation is our reliance solely on leftover material initially received for routine diagnostic purposes that we retrospectively analyzed. Using such specimens has several disadvantages: preanalytic quality of specimens could be affected by suboptimal times between sample collection and storage at -80°C because of transport and diagnostic processing time, resulting in loss in infectivity and failure of virus isolation even in the presence of high viral load. Therefore, our findings probably underestimate the true rate of infectious virus presence in symptomatic children, and we cannot comment whether our data reflect the rates of infectious virus shedding in the community. Because of the limited leftover volume of the specimens, we were unable to further investigate the quantity of infectious viral particles. Most patients were managed as outpatients and self-isolated at home, so no consecutive sampling was possible to assess infectious virus in multiple samples over the course of disease.

SARS-CoV-2 viral load and shedding patterns of culture-competent virus in 12 symptomatic children resemble those in adults. Therefore, transmission of SARS-CoV-2 from children is plausible. Considering the relatively low frequency of infected children, even in severely affected areas, biological or other unknown factors could lead to the lower transmission in this population. Large serologic investigations and systematic surveillance for acute respiratory diseases and asymptomatic presentations are needed to assess the role of children in this pandemic.

Acknowledgments

We thank Manel Essaidi-Laziosi for her help with the laboratory work and Erik Boehm for help with editing the manuscript.

About the Author

Dr. L’Huillier is a junior staff physician at Geneva University Hospitals and Faculty of Medicine, University of Geneva. His primary research interests include emerging viruses and transplant virology.

References

1. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020;323:1335. https://doi.org/10.1001/jama.2020.4344
2. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20:689–96. https://doi.org/10.1016/S1473-3099(20)30198-5
3. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al.; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 infection in children. N Engl J Med. 2020;382:1663–5. https://doi.org/10.1056/NEJMc2005073
4. World Health Organization. Report of the WHO–China Joint Mission on Coronavirus Disease 2019 (COVID-19). 28 February 2020 [cited 2020 Jun 29]. https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)
5. Parri N, Lenge M, Buonsenso D; Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med. 2020 May 1 [Epub ahead of print]. https://doi.org/10.1056/NEJMc2007617
In the current pandemic of coronavirus disease (COVID-19), detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children suspected of having the disease is essential for both infection control and establishing a definite causal relationship in unprecedented cases (1,2). However, efforts are hindered by negative SARS-CoV-2 test results for respiratory specimens and possible cross-reactivity with other coronaviruses among seropositive cases (2,3). Little is known about the value of various samples other than nasopharyngeal or oropharyngeal swab specimens in diagnosing COVID-19 and understanding the viral dynamics of SARS-CoV-2 in children. Virus RNA was persistently detected in rectal swab specimens in a previous study, although the infectiousness of the virus is unknown (4). We analyzed the viral RNA load kinetics of SARS-CoV-2 in various clinical specimens in children with COVID-19.

In South Korea, all confirmed case-patients, regardless of disease severity, must be isolated in hospitals or isolation facilities. For this study, we included all children <18 years of age who were confirmed to have COVID-19 by positive results for SARS-CoV-2 in combined nasopharyngeal and oropharyngeal swab specimens and who were hospitalized in Seoul Metropolitan Government–Seoul National University Boramae Medical Center during March 8–April 28, 2020. We extracted RNA from clinical specimens and detected SARS-CoV-2 by using the Allplex 2019-nCoV Assay kit (Seegene, http://www.seegene.com). We performed quantitation of the viral RNA with a standard curve constructed using in vitro transcribed RNA. This study was approved by the institutional review board at SMG-SNU Boramae Medical Center; written consent was waived.

We included 12 children in the study; 9 were mildly symptomatic and 3 were asymptomatic (Appendix Table 1, https://wwwnc.cdc.gov/EID/article/26/10/20-2449-App1.pdf). Median age was 6.5 years (range 27 days–16 years). Nasopharyngeal swab specimens tested positive for SARS-CoV-2 RNA in all 12 children, and 11 (92%) had positive RNA in their fecal specimens (Appendix Table 2). We collected saliva samples from 11 children; 8 (73%) tested positive. Viral RNA load in the nasopharyngeal swabs peaked early at median 7.56 (range 6.19–10.56) \( \log_{10} \) copies/mL and decreased over time (p<0.001 for trend) (Figure, panel A). The positivity of the specimens was 75% during week 2 and 55% during week 3 (Appendix Table 2). In comparison, the median initial fecal RNA load was 7.68 (range <4.10–10.27) \( \log_{10} \) copies/mL and

Along with positive SARS-CoV-2 RNA in nasopharyngeal swabs, viral RNA was detectable at high concentration for >3 weeks in fecal samples from 12 mildly symptomatic and asymptomatic children with COVID-19 in Seoul, South Korea. Saliva also tested positive during the early phase of infection. If proven infectious, feces and saliva could serve as transmission sources.
Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents

Appendix

Supplementary Methods

Our region had a SARS-CoV-2 outbreak, with an estimated 800 cases/100,000 inhabitants and reaching a seroprevalence of around 10% in the general population in early May (1). Among 638 patients <16 years old tested for SARS-CoV-2 by RT-PCR on nasopharyngeal swabs (NPS) between January 25 and March 31, 2020, 23 (3.6%) tested positive. Patients were either seen at the pediatric emergency room of the Geneva University Hospitals, or samples were received by the laboratory from other healthcare facilities as part of its function as the Swiss national reference laboratory for Emerging Viral Diseases at the Geneva University Hospitals.

All NPS specimens were collected with a flocked swab in universal transport medium (Floqswab, Copan, Italy) and tested for SARS-CoV-2 according to manufacturers’ instructions on various platforms over the course of the outbreak, including initially in house methods using eMAG extraction (bioMérieux, France) and Charité RT-PCR protocol (2), then BD SARS-CoV-2 reagent kit for BD Max system (Becton, Dickinson and Co, U.S.) and Cobas 6800 SARS CoV2 RT-PCR (Roche, Switzerland). Several diagnostic systems were used in parallel during the course of the pandemic to fulfill the steeply increasing diagnostic demand. All samples, both extracted RNA as well as remaining original specimens, were stored at −20°C and −80°C, respectively. For this study, RNA extracts of all samples were re-run with the E-gene assay (TibMolBiol, Berlin, Germany) on a Roche Light Cycler 480 (Roche Switzerland) according to manufacturers’ instructions, by using in vitro transcribed RNA for quantification (European Virus Archive) (3). Cell culture supernatant was isolated by manual extraction with Machery & Nagel Kit (Düren, Germany) and quantified by the same assay.
Clinical data of study patients were retrieved after approval by the institutional review board (Commission Cantonale d’Ethique de la Recherche [CCER] protocol 2020–00835) and documented parental consent in the medical charts.

Statistics were performed using SPSS version 23.0 (IBM Corp., 21 Armonk, NY, USA). Figures were made using GraphPad version 7.0 (LaJolla, CA, 22 USA).

References
1. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;S0140-6736(20)31304-0 [Epub ahead of print]. PubMed https://doi.org/10.1016/S0140-6736(20)31304-0

2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25. PubMed https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045

3. European Virus Archive Global (EVAg) [cited 2020 Apr 24]. https://www.european-virus-archive.com

Appendix Table. Comparison of patients with and without successful virus isolation*

| Variable                                      | Culture negative, n = 11 | Culture positive, n = 12 | p value |
|-----------------------------------------------|--------------------------|--------------------------|---------|
| Age, y, median (IQR)                         | 9.0 (3.9–12.6)           | 14.1 (1.6–15.6)          | 0.242   |
| Female sex, no. (%)                          | 5 (45)                   | 7 (58)                   | 0.537   |
| Duration of symptoms until diagnosis, d, median (IQR) | 2.0 (1.0–3.8)           | 1.5 (1.0–2.0)           | 0.373   |
| Admission, no. (%)                           | 3 (27)                   | 3 (25)                   | 0.999   |
| Diagnosis, no. (%)                           | 0.193                    |                         |         |
| Upper respiratory tract infection            | 5 (45)                   | 8 (73)                   |         |
| Pneumonia                                    | 1 (9)                    | 1 (8)                    |         |
| Fever without source                         | 1 (9)                    | 1 (9)                    |         |
| Influenza-like illness                       | 0                        | 0                        |         |
| Obstructive bronchitis                       | 1 (9)                    | 0                        |         |
| Croup                                        | 1 (9)                    | 0                        |         |
| Not reported                                 | 3 (27)                   | 0                        |         |
| Reported symptoms†                           |                          |                          |         |
| Cough                                        | 7 (88)                   | 9 (75)                   | 0.619   |
| Nasal discharge                              | 7 (88)                   | 9 (75)                   | 0.619   |
| Shortness of breath                          | 4 (50)                   | 3 (25)                   | 0.356   |
| Dysphagia                                    | 3 (38)                   | 3 (25)                   | 0.303   |
| Fever                                        | 6 (75)                   | 9 (75)                   | 0.999   |
| Arthralgia                                   | 4 (50)                   | 1 (8)                    | 0.062   |
| Myalgia                                      | 5 (63)                   | 2 (17)                   | 0.071   |
| Nausea                                       | 0                        | 3 (25)                   | 0.057   |
| Vomiting                                     | 0                        | 2 (17)                   | 0.495   |
| Diarrhea                                     | 0                        | 5 (42)                   | 0.055   |
| Abdominal pain                               | 2 (25)                   | 4 (33)                   | 0.214   |
| Anosmia                                      | 1 (13)                   | 3 (25)                   | 0.535   |
| Headache                                     | 4 (50)                   | 6 (50)                   | 0.240   |
| Fatigue                                      | 4 (50)                   | 8 (67)                   | 0.648   |
| Rash                                         | 1 (13)                   | 3 (25)                   | 0.619   |

*IQR: interquartile range
†For 3 symptomatic patients in the culture negative group, diagnosis and exact symptoms were not reported.
Appendix Figure. Cytopathic effect on VeroE6 cells inoculated at the 2nd passage with severe acute respiratory syndrome coronavirus 2 isolated from a nasopharyngeal swab sample from a child with coronavirus disease 2 days after infection (A) and uninfected control (B).